Using repurposed drugs to repair the damage that causes acute myeloid leukaemia
Targeting mutant NRAS in paediatric AML
Using an antibody 'smart bomb' to help the body fight cancer
Targeting Myeloid-Derived Suppressor Cells (MDSCs) and Tumour-Associated Macrophages (TAMs) with the anti-CD33 immunotoxin Gemtuzumab ozogamicin to restore anti-cancer immunity
Using digital technology to improve our understanding of rhabdomyosarcoma
Deep learning: An integrated approach to define clinical significance to components of the tumour microenvironment of rhabdomyosarcomas
Investigating the genetic pathways that control leukaemia growth
RNA helicase DDX3X regulates JAK-STAT signalling in acute lymphoblastic leukaemia
Can we prevent leukaemia in children?
Modelling prophylactic (microbial) prevention of childhood acute lymphoblastic leukaemia
Identifying combinations of repurposed drugs for new treatments of acute myeloid leukaemia
Facing the MuSIC - identification of synergistic repurposed drug combinations as novel therapies in paediatric acute myeloid leukaemia
Investigating what causes cells to become out of control in anaplastic large cell lymphoma
Investigation of epigenetic mechanisms of tumour growth control in anaplastic large cell lymphoma
Can we identify an 'ultra-high-risk' type of neuroblastoma?
A pilot study of expression profiling using RNAseq from formalin fixed neuroblastoma and paired diagnostic and relapsed frozen neuroblastomas.
Understanding drug resistance in neuroblastoma to develop personalised treatments
Overcoming drug resistance for efficacious neuroblastoma therapeutics